Bronchiectasis Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
See the next evidence inflection points before they arrive. This readout-outlook report connects Clinical Trials, Drug & Asset, and Company & Deal Intelligence data through PatSnap MCP Servers. Explore the PatSnap MCP Marketplace to monitor the same endpoint, sponsor and timing signals inside your own AI workflow.
MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. This is strategic research, not medical advice. Trial status, endpoints and timing can change; confirm the underlying records before making decisions.
Readout outlook: why this landscape matters now
Bronchiectasis remains an active clinical development field. The landscape is diversifying across prevention, early treatment and high-risk populations, making variant coverage, resistance, seasonality and practical delivery central to differentiation. The PatSnap evidence set used here contains 292 matched trial records and 88 indexed result records before the decision-focused sample below was selected. This companion outlook shifts the decision lens from market breadth to evidence timing: which endpoints can change practice, which sponsors can execute across geographies, and where the next readout may still leave uncertainty.
MCP workflow for a readout-focused landscape
The analysis starts with Clinical Trials MCP and clinical_trial_fetch to align phase, recruitment status, sponsor, countries, primary endpoints and completion dates. clinical_trial_result_fetch then separates already indexed evidence from future catalysts. Drug & Asset drug_fetch adds mechanism and global development status; Company & Deal Intelligence organization_fetch adds sponsor context. Use PatSnap MCP Servers to keep each layer traceable instead of inferring asset or company facts from trial titles.
Trial, endpoint and expected-readout map
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07696091 | RSS-0343 + Rifampin + Clarithromycin | Phase 1; Not yet recruiting | Reistone Biopharma Co. Ltd. | China | Cmax; The maximum plasma concentration (Day1-Day38); AUC0-t; From time 0 to the area under the blood drug concentration-time curve corresponding to the last quantifiable concentration (Day1-Day38) | 2026-09-01 |
| NCT07666841 | Intervention not normalized | Not Applicable; Not yet recruiting | Tel Aviv Sourasky Medical Center | Israel | Adherence to pulmonary rehabilitation Between the Study Groups (Assessed by a clinical research coordinator from enrollment to 6 months…) | 2028-07-01 |
| ChiCTR2600126874 | Intervention not normalized | Early Phase 1; Not yet recruiting | The First Affiliated Hospital of Nanchang University | China | Changes in sputum output (The total amount of sputum collected on days 1,2,3, and 4 during airway…) | 2027-06-30 |
| NCT07647575 | Intervention not normalized | Not Applicable; Recruiting | Taipei Veterans General Hospital | Taiwan Province | Change in Total Respiratory Severity Score (RSS) From Baseline to Month 3 (Baseline and Month 3) | 2028-04-30 |
Read the table horizontally. Phase shows nominal maturity, but endpoint choice shows what the study can actually prove; geography signals operational breadth; and expected timing reveals whether a program is a near-term catalyst or a long-duration strategic bet.
Readout signals already on record
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study (Phase 3): the indexed record reports Annualized Rate of Pulmonary Exacerbations (PEs) = 1.286 exacerbation per participant-year (95% Confidence Interval, 1.158 - 1.428); Annualized Rate of Pulmonary Exacerbations (PEs) = 1.015 exacerbation per participant-year (95% Confidence Interval, 0.910 - 1.132); Annualized Rate of Pulmonary Exacerbations (PEs): Rate ratio = 0.789(95% CI, 0.680 - 0.916), P-Value = 0.0019; Rate ratio = 0.806(95% CI, 0.694 - 0.936), P-Value = 0.0046.
- A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Evaluating Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BI 1291583 One Tablet Once Daily Over 12 Weeks Versus Placebo in Adult Patients With Cystic Fibrosis Bronchiectasis (Clairafly™) (Phase 2): the indexed record reports Occurrence of Any Treatment Emergent Adverse Events = 85.7 Percentage of participants; -; -.
- Hypertonic Saline or Carbocisteine in Bronchiectasis (Not Applicable): the indexed record reports Pulmonary exacerbations = 0.9 Event ( 0.7 - 1.09); Pulmonary exacerbations = 0.86 Event ( 0.66 - 1.06); Pulmonary exacerbations = 0.76 Event ( 0.58 - 0.95).
These signals are anchors, not league tables. Differences in population, prior treatment, baseline risk, estimand, endpoint definition and follow-up can overwhelm apparent numerical comparisons. The useful question is which uncertainty each result resolves before the next catalyst.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
How assets and sponsors shape readout probability
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including RSS-0343 (Phase 2; DPP-1), Rifampin (Approved; RNAP), Clarithromycin (Approved; 50S subunit). Company & Deal Intelligence records identify sponsor context for Reistone Biopharma Co. Ltd., Tel Aviv Sourasky Medical Center, The First Affiliated Hospital of Nanchang University, Taipei Veterans General Hospital. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Evidence white space before the next readout cycle
- Clinically meaningful endpoints paired with virologic or microbiologic measures.
- Evidence in immunocompromised, pediatric, pregnant and older populations.
- Resistance surveillance and combination strategies for prolonged infection.
- Coadministration, real-world effectiveness and implementation studies.
Readout-risk implications
A crowded field does not guarantee a crowded evidence set. Programs can still differentiate through an active comparator, a clinically meaningful endpoint, a biomarker-defined responder group, broader geography, or a credible sequencing plan. Sponsors should pressure-test whether the planned readout will close a decision gap; BD teams should distinguish mechanism novelty from evidence novelty; investors should track endpoint maturity and execution risk alongside phase.
Readout watchlist
Monitor recruitment changes, protocol amendments, primary-completion dates, new result indexing, sponsor ownership and multinational expansion. Re-run the MCP workflow as a delta analysis. A change from surrogate to clinical outcome, a delayed completion date, a new active comparator or a scaled partner can materially alter the probability and strategic meaning of the next readout.
Bottom line
Bronchiectasis has multiple clinical catalysts, but their value depends on endpoint quality, execution and context. A readout outlook is most useful when it joins trial design, indexed results, asset mechanism and sponsor capacity in one traceable view.
Build your own readout monitor: Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable components for catalyst tracking and SEO-ready reports.
